It's problem enough in this country that there are millions without health insurance coverage, but even when they do have coverage, doctors don't know what their patients' co-pays are or what their ability is to pay. But Dr. Jan Berger, Chief Clinical Officer of pharmacy giant CVS/Caremark tells the Chicago Tribune's Bruce Japsen about the movement toward evidence-based health plan design that could give patients more information in choosing medical care.
The Benefits of Evidence-Based Health Plan Design
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
It's problem enough in this country that there are millions without health insurance coverage, but even when they do have coverage, doctors don't know what their patients' co-pays are or what their ability is to pay. But Dr. Jan Berger, Chief Clinical Officer of pharmacy giant CVS/Caremark tells the Chicago Tribune's Bruce Japsen about the movement toward evidence-based health plan design that could give patients more information in choosing medical care.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Clinician's Roundtable
Challenges in AI-Driven Dermatology: Understanding Current Limitations
<p>Challenges in AI-Driven Dermatology: Understanding Current Limitations</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
ACC Action Center
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
<p>Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?